Quintrio
Home

SERVICES-MISC HEALTH & ALLIED SERVICES, NEC

Progyny, Inc. Common Stock

PGNY

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

Last trade $36.60
Day change -$0.55 (-1.48%)
Day range $36.33 – $37.33
Volume 467,277
Market cap $2.74B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.74B
Price / earnings
30.06×
Price / book
6.61×
Price / sales
2.04×
EV / sales
1.96×
EV / EBITDA
19.78×

Profitability

Earnings per share
$1.24
Return on assets
13.47%
Return on equity
21.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.93×
Quick ratio
1.93×
Cash ratio
0.49×

Cash flow

Price / cash flow
13.21×
Price / free cash flow
15.23×
Free cash flow
$179.64M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PGNY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$341.25M$350.51M$328.5M$318.4M$313.35M$332.87M$324.04M$298.43M
Cost of revenue$257.51M$261.21M$245.43M$241.52M$240.51M$253.9M$248.24M$235M
Gross profit$83.74M$89.3M$83.07M$76.88M$72.84M$78.97M$75.8M$63.43M
Selling, general and administrative$48.56M$49.3M$47.69M$61.66M$51.31M$54.62M$51.63M$47.65M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$48.56M$49.3M$47.69M$61.66M$51.31M$54.62M$51.63M$47.65M
Operating income$35.18M$40M$35.38M$15.22M$21.53M$24.36M$24.17M$15.79M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$36.42M$41.14M$36.88M$17.85M$23.96M$27.08M$26.54M$17.66M
Income taxes$10.16M$13.09M$12.65M$5.37M$10.1M$9.97M$11.48M$7.13M
Net income$26.25M$28.05M$24.23M$12.49M$13.86M$17.11M$15.06M$10.53M
Net income attributable to common shareholders$26.25M$28.05M$24.23M$12.49M$13.86M$17.11M$15.06M$10.53M
EBITDA$37.33M$41.63M$36.86M$16.59M$22.8M$25.56M$25.28M$16.66M
Basic earnings per share$0.34$0.36$0.30$0.15$0.16$0.20$0.18$0.12
Diluted earnings per share$0.32$0.34$0.29$0.14$0.15$0.19$0.17$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know

Progyny (PGNY), a fertility and family building benefits provider, has earned a Momentum Style Score of A and a Zacks Rank #2 (Buy) rating. The stock has outperformed its industry significantly, gaining 3.85% weekly, 34.7% monthly, and 47.37% annually, compared to the S&P 500's 13.41% yearly return. Recent earnings estimate revisions have also been positive, with upward revisions for both current and next fiscal year estimates.

The Motley Fool

Progyny: 3 Key Takeaways for Long-Term Investors

Progyny reported record results for its 2026 selling season, adding 1.3 million covered lives across 85+ new clients, bringing total coverage to 8.3 million for 2027. The company benefits from competitor exits and restructuring, strengthening its market position. Management raised full-year guidance and has repurchased over 14 million shares since November 2025, demonstrating strong cash generation and shareholder returns.

Zacks Investment Research

Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?

Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.

Zacks Investment Research

PGNY or CRL: Which Is the Better Value Stock Right Now?

A comparison of two Medical Services stocks reveals that Progyny (PGNY) presents a more attractive value investment opportunity than Charles River Laboratories (CRL). PGNY has a Zacks Rank of #2 (Buy) versus CRL's #3 (Hold), along with superior valuation metrics including a lower forward P/E ratio (12.40 vs 26.89) and a better Value grade (B vs D).

Zacks Investment Research

PGNY vs. CRL: Which Stock Is the Better Value Option?

A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.